Themis Medicare Ltd
NSE: THEMISMED BSE: 530199
₹85.80
(-1.20%)
Wed, 11 Mar 2026, 03:15 am
Market Cap7.95B
PE Ratio0
Dividend0.58
Health Technology
Pharmaceuticals: Major
24.5KThemis Medicare Analysis
dividend
- Dividends paid are thoroughly covered by earnings (15.4x coverage).
- Dividends per share have fallen over the past 10 years.
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Themis Medicare's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Themis Medicare's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Themis Medicare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Themis Medicare is profitable, therefore cash runway is not a concern.
- Themis Medicare is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 2x debt.
- Themis Medicare's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (236.8% vs 48.2% today).
- Debt is not well covered by operating cash flow (0.4%, less than 20% of total debt).
- Interest payments on debt are not well covered by earnings (EBIT is 2.1x annual interest expense, ideally 3x coverage).
- Themis Medicare's level of debt (48.2%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Themis Medicare board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Sachin's compensation has increased in line with Themis Medicare recently becoming profitable.
- The tenure for the Themis Medicare management team is about average.
- Sachin's remuneration is higher than average for companies of similar size in India.
misc
- Themis Medicare is not covered by any analysts.
past
- Themis Medicare used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Themis Medicare has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
- Themis Medicare's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
- Themis Medicare's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Themis Medicare has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Themis Medicare has become profitable in the last year making it difficult to compare the IN Pharmaceuticals industry average.
value
- Themis Medicare is good value based on assets compared to the IN Pharmaceuticals industry average.
- Themis Medicare is good value based on earnings compared to the IN Pharmaceuticals industry average.
- THEMISMED outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- THEMISMED outperformed the Market in India which returned -14.5% over the past year.
- Themis Medicare's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Themis Medicare's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Themis Medicare is overvalued based on earnings compared to the India market.
- NSEI:THEMISMED is down -1.7% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:THEMISMED is down -1.7% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800